VILLA GUARDIA, Italy--(BUSINESS WIRE)--Gentium S.p.A. (NASDAQ: GENT) (the "Company") today announced that the Court of Como issued a decision terminating the legal proceeding brought in August against ...
Ireland's Jazz Pharmaceuticals ($JAZZ) is betting $1 billion that Italian biotech Gentium ($GENT) and its orphan treatment Defitelio can sustain their momentum ...
BREAKING: Helicopter crashes into Hudson River in New York City Profile Sections Local tv Featured More From NBC Follow NBC News news Alerts There are no new alerts at this time VILLA GUARDIA, Italy, ...
With the Nasdaq Biotechnology Index up 65% since the start of the year, it's clear that the biotech sector performed extraordinarily well in 2013 -- but which stocks were the biggest winners? Several ...
BANGALORE, Aug 19 (Reuters) - Italian biopharmaceutical firm Gentium S.p.A. said its experimental drug to treat the blockage of small veins in the liver missed the main goal of a late-stage study, ...
Jazz Pharmaceuticals said it will buy Gentium for about $1 billion in a deal that will bolster Jazz’ portfolio of rare-disease drugs—notably the acquired company’s lead product Defitelio (defibrotide) ...
What: Dr. Laura Ferro, President and CEO of Gentium SpA (GENT), will preside over the closing bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Monday, ...
"The complex nature of [Defitelio] could make it difficult to copy, so we believe it possible that generic competition might not emerge," FBR's William Tanner says, regarding Jazz Pharmaceuticals' ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback